A simple decision tree model was developed using Excel ® describing costs and consequences associated with two main parameters: risk of nosocomial infection due to the contamination of strips and risk of hypoglycemia/hyperglycemia due to an error in the determination of glycemia induced by the storage conditions of the strips. For each alternative (IP and VP), a simulated cohort of 1000 patients went through the tree accounting for costs and effects, and the results were expressed as hypoglycemic events, nosocomial infection events, use/waste of strips, QALYs and ICER.
METHODS:
A simple decision tree model was developed using Excel ® describing costs and consequences associated with two main parameters: risk of nosocomial infection due to the contamination of strips and risk of hypoglycemia/hyperglycemia due to an error in the determination of glycemia induced by the storage conditions of the strips. For each alternative (IP and VP), a simulated cohort of 1000 patients went through the tree accounting for costs and effects, and the results were expressed as hypoglycemic events, nosocomial infection events, use/waste of strips, QALYs and ICER. Uncertainty was tested using one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Cost-effectiveness acceptability curve with a threshold of 25.000€/QALY was drawn. Probabilistic results were depicted using a CE plane.
The aim of this economic evaluation is to compare individually and vial-packaged strips for glucose monitoring in a hospital setting in order to figure out if the use of individually-packaged strips decrease costs and increase utility associated to hypoglycemic/hyperglycemic events and nosocomial infections.
RESULTS:
The lack of data made us to work with a few assumptions along with the available resources. Those are shown in table 1. The probability of hypoglycemic events are derived from Keffer et al., 1998 who stated a relationship between the accumulated time a vial is open and the error of the estimation. We have fitted a curve to those date trying to have values further than the 2 hours shown in the paper. From this exercise we have developed the assumptions about strips wasted. Table 1 Parameters used in the model CONCLUSIONS: Under the assumption of wrong measurements due to bad storage conditions, the use of individual packaged strips is a dominant option over vial-packaged strips, reducing costs by a 25%. The difference in the number of hypoglycemic events is anomaly high and is due to the fitted curve used from Keffer et al., this figures will be reviewed and discussed within an expert panel to include more realistic data to the model in further research.
References: We have assumed as well the reductions in events when IP strips are used. This conservative value has been tested using the OWSA and the PSA. Individual packaged strips save money (1,162 € per patient) and get more QALYs (0.023 per patient) (Figure 1) , which confers a dominant position to individual packaged strips with 11% less nosocomial events, 10 times less hypoglycemic events (53 vs 655) and 6% reduction in the use of strips. PSA shows results in the same direction with a 64% probability of being cost-effective under a threshold of 25,000 € (from 82% at 0 € and keeping the difference over 25,000 €). (Figure 2 
